Vangsted AJ - Search Results

1

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.

Erickson SW, Stephens OW, Chavan SS, Tian E, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ. Erickson SW, et al. Among authors: vangsted aj. Leukemia. 2015 Dec;29(12):2418-21. doi: 10.1038/leu.2015.238. Epub 2015 Aug 26. Leukemia. 2015. PMID: 26308770 Free PMC article. No abstract available.

2

Drug response prediction in high-risk multiple myeloma.

Vangsted AJ, Helm-Petersen S, Cowland JB, Jensen PB, Gimsing P, Barlogie B, Knudsen S. Vangsted AJ, et al. Gene. 2018 Feb 20;644:80-86. doi: 10.1016/j.gene.2017.10.071. Epub 2017 Nov 6. Gene. 2018. PMID: 29122646 Clinical Trial.

3

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.

Nielsen KR, Rodrigo-Domingo M, Steffensen R, Baech J, Bergkvist KS, Oosterhof L, Schmitz A, Bødker JS, Johansen P, Vogel U, Vangsted A, Dybkær K, Bøgsted M, Johnsen HE. Nielsen KR, et al. Leuk Lymphoma. 2017 Nov;58(11):2695-2704. doi: 10.1080/10428194.2017.1306643. Epub 2017 Apr 9. Leuk Lymphoma. 2017. PMID: 28393658

4

Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.

Hermansen NE, Borup R, Andersen MK, Vangsted AJ, Clausen NT, Kristensen DL, Nielsen FC, Gimsing P. Hermansen NE, et al. Among authors: vangsted aj. Int J Lab Hematol. 2016 Jun;38(3):298-307. doi: 10.1111/ijlh.12486. Epub 2016 Mar 29. Int J Lab Hematol. 2016. PMID: 27027250 Clinical Trial.

5

The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.

Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U. Vangsted AJ, et al. Bone Marrow Transplant. 2009 Apr;43(7):539-45. doi: 10.1038/bmt.2008.351. Epub 2008 Nov 10. Bone Marrow Transplant. 2009. PMID: 18997828

6

Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.

Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM. Brimnes MK, et al. Among authors: vangsted aj. Scand J Immunol. 2010 Dec;72(6):540-7. doi: 10.1111/j.1365-3083.2010.02463.x. Scand J Immunol. 2010. PMID: 21044128 Free article.

7

Early infections in patients undergoing high-dose treatment with stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma.

Gang AO, Arpi M, Gang UJ, Vangsted AJ. Gang AO, et al. Among authors: vangsted aj. Hematology. 2010 Aug;15(4):222-9. doi: 10.1179/102453309X12583347113979. Hematology. 2010. PMID: 20670481

8

[Novel medical treatment modalities in hematology].

Hasselbalch HC, Birgens H, Dufva IH, Dalseg AM, Brown Pde N, Jensen MK, Vangsted A. Hasselbalch HC, et al. Ugeskr Laeger. 2008 Jun 9;170(24):2115-9. Ugeskr Laeger. 2008. PMID: 18565291 Review. Danish.

9

The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.

Szabo AG, Thorsen J, Iversen KF, Levring MB, Helleberg C, Hermansen E, Bønløkke ST, Nielsen K, Teodorescu EM, Kurt E, Strandholdt CN, Vangsted AJ. Szabo AG, et al. Among authors: vangsted aj. EJHaem. 2023 Aug 24;4(4):1006-1012. doi: 10.1002/jha2.774. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024635 Free PMC article.

10

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.

van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Grasso M, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro M, Gay F, Sonneveld P, Musto P. van de Donk NWCJ, et al. Among authors: vangsted aj. Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14. Lancet Oncol. 2023. PMID: 37717583 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page